So I guess this is why this drug is being used. Spasticity reduction. Only two years for your competent? doctor to figure how to treat your spasticity. Is your doctor competent at all?
Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke October 2022
The latest here:
Combining cyproheptadine hydrochloride with targeted muscle activation training to treat upper extremity stroke: A randomized, placebo-controlled trial
Archives of Physical Medicine and Rehabilitation. Volume 105(10), Pgs. 1938-1945.
NARIC Accession Number: J94231. What's this?
Author(s): Kamper, Derek, Bansal, Naveen, Barry, Alexander, Seo, Na J., Celian, Courtney, Vidakovic, Lynn, Stoykov, Mary E., Roth, Elliot.
Publication Year: 2024.
Abstract: Study evaluated a treatment for upper-extremity impairment in stroke survivors that combines administration of cyproheptadine hydrochloride with repetitive practice focused on control of muscle activation patterns. Participants received either a placebo or cyproheptadine hydrochloride in identical pill form. The daily dosage of cyproheptadine/placebo was gradually increased from 8 to 24 milligrams per day over 3 weeks and then maintained over the next 6 weeks while participants completed 18 therapy sessions. Therapy consisted of either: (1) active practice of muscle activation patterns to play "serious" computer games or control a custom hand exoskeleton or (2) passive, cyclical finger stretching imposed by the exoskeleton. Ninety-four stroke survivors with severe, chronic hand impairment were randomly assigned to 1 of 4 treatment groups (cyproheptadine-active, cyproheptadine-stretching, placebo-active, or placebo-stretching). The primary outcome was time to complete the Graded Wolf Motor Function Test (GWMFT); secondary outcome measures included finger strength and spasticity. Across the 88 participants who completed the study, a repeated-measures analysis of variance revealed a significant effect of group-by-evaluation interaction on GWMFT. The 3 groups receiving cyproheptadine and/or actively practicing muscle activation pattern control exhibited significant reduction in mean time to complete the GWMFT tasks; roughly one-third of these participants experienced at least a 10 percent reduction in completion time. Gains were maintained at the 1-month follow-up evaluation. The group receiving placebo and passive stretching did not show improvement. No significant differences among groups were observed in terms of changes in strength or spasticity.
Descriptor Terms: DEXTERITY, DRUGS, EXERCISE, LIMBS, MOTOR SKILLS, MUSCULAR IMPAIRMENTS, PHARMACOLOGY, REHABILITATION TECHNOLOGY, ROBOTICS, STROKE, THERAPEUTIC TRAINING.
Can this document be ordered through NARIC's document delivery service*?: Request Information.
Citation: Kamper, Derek, Bansal, Naveen, Barry, Alexander, Seo, Na J., Celian, Courtney, Vidakovic, Lynn, Stoykov, Mary E., Roth, Elliot. (2024.) Combining cyproheptadine hydrochloride with targeted muscle activation training to treat upper extremity stroke: A randomized, placebo-controlled trial. Archives of Physical Medicine and Rehabilitation., 105(10), Pgs. 1938-1945. Retrieved 11/20/2024, from REHABDATA database.
NARIC Accession Number: J94231. What's this?
Author(s): Kamper, Derek, Bansal, Naveen, Barry, Alexander, Seo, Na J., Celian, Courtney, Vidakovic, Lynn, Stoykov, Mary E., Roth, Elliot.
Publication Year: 2024.
Abstract: Study evaluated a treatment for upper-extremity impairment in stroke survivors that combines administration of cyproheptadine hydrochloride with repetitive practice focused on control of muscle activation patterns. Participants received either a placebo or cyproheptadine hydrochloride in identical pill form. The daily dosage of cyproheptadine/placebo was gradually increased from 8 to 24 milligrams per day over 3 weeks and then maintained over the next 6 weeks while participants completed 18 therapy sessions. Therapy consisted of either: (1) active practice of muscle activation patterns to play "serious" computer games or control a custom hand exoskeleton or (2) passive, cyclical finger stretching imposed by the exoskeleton. Ninety-four stroke survivors with severe, chronic hand impairment were randomly assigned to 1 of 4 treatment groups (cyproheptadine-active, cyproheptadine-stretching, placebo-active, or placebo-stretching). The primary outcome was time to complete the Graded Wolf Motor Function Test (GWMFT); secondary outcome measures included finger strength and spasticity. Across the 88 participants who completed the study, a repeated-measures analysis of variance revealed a significant effect of group-by-evaluation interaction on GWMFT. The 3 groups receiving cyproheptadine and/or actively practicing muscle activation pattern control exhibited significant reduction in mean time to complete the GWMFT tasks; roughly one-third of these participants experienced at least a 10 percent reduction in completion time. Gains were maintained at the 1-month follow-up evaluation. The group receiving placebo and passive stretching did not show improvement. No significant differences among groups were observed in terms of changes in strength or spasticity.
Descriptor Terms: DEXTERITY, DRUGS, EXERCISE, LIMBS, MOTOR SKILLS, MUSCULAR IMPAIRMENTS, PHARMACOLOGY, REHABILITATION TECHNOLOGY, ROBOTICS, STROKE, THERAPEUTIC TRAINING.
Can this document be ordered through NARIC's document delivery service*?: Request Information.
Citation: Kamper, Derek, Bansal, Naveen, Barry, Alexander, Seo, Na J., Celian, Courtney, Vidakovic, Lynn, Stoykov, Mary E., Roth, Elliot. (2024.) Combining cyproheptadine hydrochloride with targeted muscle activation training to treat upper extremity stroke: A randomized, placebo-controlled trial. Archives of Physical Medicine and Rehabilitation., 105(10), Pgs. 1938-1945. Retrieved 11/20/2024, from REHABDATA database.
No comments:
Post a Comment